Sunresin and ChromaGenix Partner to Expand Global Access to AAV Purification Technologies

The collaboration is designed to expand access to advanced AAV purification technologies and provide stronger regional support for cell and gene therapy developers across Asia, Europe and the Americas.

AAV manufacturing has made remarkable progress, but downstream purification remains one of its toughest bottlenecks. Different serotypes can behave very differently during purification, and for developers working across multiple vector candidates, that can mean redesigning the capture step again and again. The result is more development work, greater validation complexity and additional pressure on timelines and manufacturing costs.

Sunresin and ChromaGenix are now working together to address that challenge. The two companies have announced a collaboration to expand access to advanced chromatography technologies for AAV purification, combining ChromaGenix’s synthetic ligand-based technology with Sunresin’s capabilities in chromatography resin development, manufacturing, supply and technical support.

At the centre of the collaboration is AvXcel™, an affinity capture technology designed to work across AAV1–9, rh10, select engineered serotypes and novel capsids. For developers managing increasingly diverse viral vector pipelines, broader serotype coverage could help reduce the need to build a new capture strategy for every candidate and support a more platform-oriented approach to downstream development.

Its synthetic ligand design also enables near-neutral elution conditions. This can be particularly valuable in AAV processing, where harsh acidic conditions may affect functional recovery and often require rapid neutralization. By moving closer to neutral conditions, the technology is designed to simplify this part of the workflow while supporting recovery of functional vector.

“Broad serotype coverage can simplify downstream development and reduce the need to redesign the capture step for every new AAV candidate,” said Chris Major, CEO of ChromaGenix, highlighting how AvXcel can reduce the need to redesign capture for each new AAV candidate while opening additional process options through its synthetic ligand design.

The collaboration goes beyond capture. It also includes two novel resins for the selective removal of host cell proteins and DNA from viral vector and antibody process streams. Together, the technologies address two important parts of downstream processing: capturing the target efficiently and removing process-related impurities.

Technology, however, is only useful when development teams can access it, evaluate it and receive the support needed to implement it. That is another important part of the agreement. Sunresin will supply and support the resins across Asian markets, while ChromaGenix will continue to serve customers in Europe and the Americas. The regional model is intended to bring technical discussion and practical support closer to customers as they assess the technologies in their own processes.

Fred Ghanem, Vice President of the Life Science Division at Sunresin, described the need for purification technologies that are “technically robust, scalable and easier to apply across different AAV programs.”

The partnership combines ChromaGenix’s expertise in synthetic peptide ligand-based purification technologies with Sunresin’s chromatography development, resin manufacturing, supply reliability and customer support network in Asia. Together, the companies aim to give cell and gene therapy developers a practical route to evaluate broad-coverage AAV capture and selective impurity removal within their downstream strategies.

This comes at a time when AAV pipelines are becoming more diverse and manufacturing expectations are rising. Recovery, impurity clearance, process consistency and scalability all remain central to the transition from development to robust manufacturing. Purification technologies that can be applied across more programs could therefore remove an important layer of complexity from that journey.

For Sunresin and ChromaGenix, the collaboration has a clear objective: make advanced AAV purification technologies easier to access and apply globally. By connecting broader serotype coverage with impurity-removal tools, scalable resin manufacturing and regional technical support, the companies aim to help developers build cleaner, more consistent and more scalable processes for the next generation of cell and gene therapies.